The concern of generic rivalry has long loomed above copyright’s blockbuster drug, Viagra, raising questions about the prospects of connected drug ventures. While early years saw significant gains, the intellectual property expiration has created the way for discounted substitutes, possibly lowering profitability and presenting a genuine risk for